PharmExec Blog
Follow Us
RSS
Bookstore
Monthly Archives: April 2011
AstraZeneca Signs Exclusive Distribution Deal for Vandetanib
As the number of drugs targeting small populations increases, managing numerous drug distribution channels and educating the relevant parties – specialty pharmacists, payers, physicians, and patients – becomes a daunting task. Specialty pharmacies that handle seven to 10 major disease states, after all, might only see three or four patients with a given rare disease, [...]
Posted in Deals, FDA, Legal, Market Access, Regulatory, Strategy, healthcare, pricing Tagged distribution, Orphan Drugs, Pharmacy, Ultra Orphan Leave a comment
Warner-Chilcott's Cuts in Europe — Good News for US?
Any company announcing plans to ‘restructure’ and ‘repurpose’ itself tends to send out tremors across the industry, but for US employees of Dublin-headquartered Warner-Chilcott — the latest firm to use these tried and tested euphemisms — this could fuel a sigh of relief.
A Blueprint for FDA Reform
The FDA five-year strategy emphasizes a more coordinated—and skeptical—response to globalization of the drug supply chain. On balance, the strategy continues to focus more on managing risk than assessing benefit—industry take heed.
Earlier this month, FDA released a five-year, forward-looking strategic priorities report—“Responding to the Public Health Challenges of the 21st Century”—that outlines what the industry [...]
More States Follow Washington's Value-Based Lead
Cameron McClearn looks at how Washington State’s approach to health care value is beginning to influence the rest of the country.
Many trends start on the West Coast and migrate to the rest of the nation. The Washington State health care system is worth watching as officials evaluate the economic value of medical treatments for state [...]
Posted in healthcare, pricing Tagged evidenced-based rationing, health economics, HTA, Medicaid, Medicare, value, value-based 2 Comments
Emerging Markets: Looking Beyond the Heady Growth Numbers